RBD4059

DRUG2 trials

Sponsors

Suzhou Ribo Life Science Co. Ltd., Ribocure Pharmaceuticals AB

Conditions

Healthy VolunteersStable Coronary Artery Disease CAD

Phase 1

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

CompletedNCT05653037

Suzhou Ribo Life Science Co. Ltd.Healthy Volunteers

Start: 2023-03-21End: 2025-11-10Updated: 2026-09-01

Phase 2

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

CompletedNCT06717074

Ribocure Pharmaceuticals ABStable Coronary Artery Disease CAD

Start: 2024-08-28End: 2026-04-29Updated: 2026-05-27

Related Papers

RNA interference therapy targeting coagulation factor XI - a first-in-human trial of RBD4059.

2026-01-09

First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects

European Heart Journal2024-10-011 citations